The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 72.50
Bid: 60.00
Ask: 85.00
Change: -3.50 (-4.61%)
Spread: 25.00 (41.667%)
Open: 72.50
High: 72.50
Low: 72.50
Prev. Close: 76.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update - Replacement

2 Aug 2022 08:59

RNS Number : 5961U
Biome Technologies PLC
02 August 2022
 

The following amendment has been made to the Trading Update announcement released at 07:00 on 2 August 2022 under RNS No. 5230U.

In the Cash and liquidity section, the announcement incorrectly stated the reference date for the comparative cash balance as being 30 June 2022. The correct comparative cash balance reference date is 30 June 2021. 

All other details remain unchanged. The full corrected announcement is set out below.

The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

 

2 August 2022

 

 

Biome Technologies plc

 

("Biome", "the Company" or "the Group")

 

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today provides an unaudited Trading Update for the quarter ended 30 June 2022. The Company's unaudited interim results are expected to be announced on 22 September 2022.

 

Group revenues for the quarter ended 30 June 2022 were slightly lower than management expectations at £1.4m (Q2 2021: £1.3m) as delays of materials from suppliers constrained both Divisions. It is expected that the revenues delayed from Q2 will be recovered during Q3 2022.

 

Bioplastics Division

 

The Division's revenues for Q2 were £1.0m (Q2 2021: £1.1m). Management continues to anticipate substantial revenue growth from this Division during H2 2022. This growth is underpinned by supply chain preparation and stocking by several of the Division's customers which are planning product launches in H1 2023 and based on our new "home compostable" bio-based and biodegradable materials that are subject to the protection of a pending patent. Enquiries in the bioplastics space remain buoyant, although our customers continue to face supply chain challenges as they deploy new products.

 

Stanelco RF Technologies Division

 

Revenues in the RF Technologies Division in Q2 were £0.2m (Q2 2021: £0.2m). The Division's strong orderbook had been expected to convert to higher revenue levels in Q2. However, component shortages, particularly of electronic parts, have impeded the build out of the significant RF contracts that were announced in late 2021 and early 2022. Good progress has already been made in early Q3 and we expect for the Division's delayed revenues to be fully recovered in H2.

 

Cash and liquidity

 

The Group had a cash balance as at 30 June 2022 of £0.7m (30 June 2021: £1.4m) and no bank debt.

 

We are pleased to announce that the Group has entered into a receivables financing agreement with Accelerated Payments Limited. This highly flexible facility has been put in place to provide working capital funding, as and when required, as we look to grow the business over the coming months and years.

 

Group Outlook

 

The Board's view of the Group's performance remains in line with current market expectations.

 

 

-Ends-

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

Rob Smith, Chief Financial Officer

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Sales and Corporate Broking)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

The Group comprises two divisions, Biome Bioplastics Limited ("Bioplastic") and Stanelco RF Technologies Limited ("RF Technologies").

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil- based polymers.

Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

www.biometechnologiesplc.com www.biomebioplastics.com and www.thinkbioplastic.com www.stanelcorftechnologies.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKZGGRNZKGZZG
Date   Source Headline
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.